Panbela Therapeutics Inc
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal ad… Read more
Panbela Therapeutics Inc (PBLA) - Net Assets
Latest net assets as of September 2024: $-18.17 Million USD
Based on the latest financial reports, Panbela Therapeutics Inc (PBLA) has net assets worth $-18.17 Million USD as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($5.17 Million) and total liabilities ($23.34 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-18.17 Million |
| % of Total Assets | -351.55% |
| Annual Growth Rate | N/A |
| 5-Year Change | -440.07% |
| 10-Year Change | N/A |
| Growth Volatility | 282.14 |
Panbela Therapeutics Inc - Net Assets Trend (2011–2023)
This chart illustrates how Panbela Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Panbela Therapeutics Inc (2011–2023)
The table below shows the annual net assets of Panbela Therapeutics Inc from 2011 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $-4.71 Million | +41.48% |
| 2022-12-31 | $-8.05 Million | -178.82% |
| 2021-12-31 | $10.21 Million | +20.88% |
| 2020-12-31 | $8.45 Million | +509.96% |
| 2019-12-31 | $1.39 Million | +416.79% |
| 2018-12-31 | $268.00K | +107.26% |
| 2017-12-31 | $-3.69 Million | +20.53% |
| 2016-12-31 | $-4.64 Million | -73.14% |
| 2015-12-31 | $-2.68 Million | -1170.86% |
| 2014-12-31 | $-210.96K | -52.99% |
| 2013-12-31 | $-137.89K | -237.58% |
| 2012-12-31 | $-40.85K | +89.91% |
| 2011-12-31 | $-404.99K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Panbela Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11157964900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Comprehensive Income | $745.00K | % |
| Other Components | $120.04 Million | % |
| Total Equity | $-4.71 Million | 100.00% |
Panbela Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Panbela Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Instituto Rosenbusch S.A.
BA:ROSE
|
$1.57 Million |
|
MARKETAXESS HOLDING
MU:MWI
|
$1.57 Million |
|
ALUMINIUM DU MAROC
BC:ALUMINIUM-DU-MAROC
|
$1.57 Million |
|
NICE CALL PUBLIC COMPANY LIMITED
BK:NCP
|
$1.57 Million |
|
Dalrada Financial Corp
PINK:DFCO
|
$1.57 Million |
|
Gossan Resources Ltd
V:GSS
|
$1.57 Million |
|
Agentix Corp
PINK:AGTX
|
$1.57 Million |
|
Intra Energy Corporation
AU:IEC
|
$1.57 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Panbela Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from -8,049,000 to -4,710,000, a change of 3,339,000.
- Net loss of 25,263,000 reduced equity.
- Share repurchases of 10,000 reduced equity.
- New share issuances of 23,053,000 increased equity.
- Other comprehensive income decreased equity by 14,000.
- Other factors increased equity by 5,573,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-25.26 Million | -536.37% |
| Share Repurchases | $10.00K | -0.21% |
| Share Issuances | $23.05 Million | +489.45% |
| Other Comprehensive Income | $-14.00K | -0.3% |
| Other Changes | $5.57 Million | +118.32% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Panbela Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $-3374.92 | $0.34 | x |
| 2012-12-31 | $-340.39 | $0.34 | x |
| 2013-12-31 | $-1149.10 | $0.34 | x |
| 2014-12-31 | $-1757.99 | $0.34 | x |
| 2015-12-31 | $-2287.54 | $0.34 | x |
| 2016-12-31 | $-1792.97 | $0.34 | x |
| 2017-12-31 | $-1241.67 | $0.34 | x |
| 2018-12-31 | $68.98 | $0.34 | x |
| 2019-12-31 | $5831.33 | $0.34 | x |
| 2020-12-31 | $26219.74 | $0.34 | x |
| 2021-12-31 | $20931.38 | $0.34 | x |
| 2022-12-31 | $-9389.00 | $0.34 | x |
| 2023-12-31 | $-43334.25 | $0.34 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Panbela Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-215.90%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 0.00% | -19.77% | 2.76x | 0.00x | $-97.81K |
| 2012 | 0.00% | 20.07% | 2.02x | 0.00x | $251.46K |
| 2013 | 0.00% | -21.77% | 1.83x | 0.00x | $-198.23K |
| 2014 | 0.00% | -7.89% | 3.33x | 0.00x | $-85.95K |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.66 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.65 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-10.01 Million |
| 2018 | -2203.36% | 0.00% | 0.00x | 7.08x | $-5.93 Million |
| 2019 | -447.65% | 0.00% | 0.00x | 2.27x | $-6.34 Million |
| 2020 | -56.44% | 0.00% | 0.00x | 1.16x | $-5.61 Million |
| 2021 | -99.25% | 0.00% | 0.00x | 1.26x | $-11.16 Million |
| 2022 | 0.00% | 0.00% | -0.33x | 0.00x | $-34.13 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-24.79 Million |
Industry Comparison
This section compares Panbela Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Panbela Therapeutics Inc (PBLA) | $-18.17 Million | 0.00% | N/A | $1.57 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |